Teva Unit Tells High Court Not To Take Up Horizon's IP Loss
Teva Pharmaceuticals unit Actavis has urged the U.S. Supreme Court not to take up Horizon's appeal over a divided Federal Circuit ruling that struck down part of its patented arthritis drug...To view the full article, register now.
Already a subscriber? Click here to view full article